Free Trial

Surmodics (SRDX) Stock Price, News & Analysis

Surmodics logo
$33.30 -0.73 (-2.13%)
As of 02:52 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

About Surmodics Stock (NASDAQ:SRDX)

Key Stats

Today's Range
$33.14
$33.90
50-Day Range
$28.81
$38.00
52-Week Range
$26.00
$40.38
Volume
144,904 shs
Average Volume
193,353 shs
Market Capitalization
$476.19 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$43.00
Consensus Rating
Hold

Company Overview

Surmodics Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
89th Percentile Overall Score

SRDX MarketRank™: 

Surmodics scored higher than 89% of companies evaluated by MarketBeat, and ranked 124th out of 938 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Surmodics has received a consensus rating of Hold. The company's average rating score is 2.25, and is based on 1 buy rating, 3 hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Surmodics has only been the subject of 2 research reports in the past 90 days.

  • Read more about Surmodics' stock forecast and price target.
  • Earnings Growth

    Earnings for Surmodics are expected to grow by 300.00% in the coming year, from $0.20 to $0.80 per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Surmodics is -27.25, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Surmodics is -27.25, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Surmodics has a P/B Ratio of 4.30. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Read more about Surmodics' valuation and earnings.
  • Percentage of Shares Shorted

    3.05% of the float of Surmodics has been sold short.
  • Short Interest Ratio / Days to Cover

    Surmodics has a short interest ratio ("days to cover") of 2.3, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Surmodics has recently increased by 8.53%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    Surmodics does not currently pay a dividend.

  • Dividend Growth

    Surmodics does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    3.05% of the float of Surmodics has been sold short.
  • Short Interest Ratio / Days to Cover

    Surmodics has a short interest ratio ("days to cover") of 2.3, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Surmodics has recently increased by 8.53%, indicating that investor sentiment is decreasing significantly.
  • News Sentiment

    Surmodics has a news sentiment score of 1.71. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.69 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 8 news articles for Surmodics this week, compared to 3 articles on an average week.
  • Search Interest

    2 people have searched for SRDX on MarketBeat in the last 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Surmodics insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    Only 8.90% of the stock of Surmodics is held by insiders.

  • Percentage Held by Institutions

    96.63% of the stock of Surmodics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Surmodics' insider trading history.
Receive SRDX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Surmodics and its competitors with MarketBeat's FREE daily newsletter.

By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

SRDX Stock News Headlines

Musk Warns. Trump Acts. Your Retirement May Depend on It
With Donald Trump back in the White House, many believe an economic revival could be underway — but it also brings new risks for retirement savers. Traditional 401(k)s and IRAs may leave investors more exposed than they realize. That’s why a Trump-backed IRS strategy is gaining attention. It allows everyday Americans to reposition their retirement savings into real assets like gold and silver — offering both protection and potential upside. A new 2025 Wealth Protection Guide explains exactly how it works.tc pixel
What's Next: Surmodics's Earnings Preview
Surmodics (SRDX) Q3 EPS Turns Positive
See More Headlines

SRDX Stock Analysis - Frequently Asked Questions

Surmodics' stock was trading at $39.60 at the beginning of 2025. Since then, SRDX shares have decreased by 15.4% and is now trading at $33.52.

Surmodics, Inc. (NASDAQ:SRDX) posted its quarterly earnings data on Friday, August, 8th. The company reported $0.06 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.21) by $0.27. The firm earned $29.57 million during the quarter, compared to analyst estimates of $28.04 million. Surmodics had a negative net margin of 14.59% and a negative trailing twelve-month return on equity of 2.99%.

Top institutional investors of Surmodics include Alliancebernstein L.P. (5.95%), Gabelli Funds LLC (2.90%), Hudson Bay Capital Management LP (2.80%) and Hudson Bay Capital Management LP (2.80%). Insiders that own company stock include Timothy J Arens, David Dantzker, Ronald B Sr Kalich Sr and Jose H Bedoya.
View institutional ownership trends
.

Shares of SRDX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Surmodics investors own include NVIDIA (NVDA), Meta Platforms (META), Broadcom (AVGO), Advanced Micro Devices (AMD), Adobe (ADBE), ServiceNow (NOW) and Palo Alto Networks (PANW).

Company Calendar

Last Earnings
8/08/2025
Today
9/04/2025
Fiscal Year End
9/30/2025
Next Earnings (Estimated)
11/05/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED PRODUCTS
Sub-Industry
Health Care Equipment
Current Symbol
NASDAQ:SRDX
CIK
924717
Employees
450
Year Founded
1979

Price Target and Rating

High Price Target
$43.00
Low Price Target
$43.00
Potential Upside/Downside
+26.4%
Consensus Rating
Hold
Rating Score (0-4)
2.25
Research Coverage
4 Analysts

Profitability

EPS (Trailing Twelve Months)
($1.23)
Trailing P/E Ratio
N/A
Forward P/E Ratio
170.15
P/E Growth
N/A
Net Income
-$11.54 million
Net Margins
-14.59%
Pretax Margin
-12.16%
Return on Equity
-2.99%
Return on Assets
-1.99%

Debt

Debt-to-Equity Ratio
0.27
Current Ratio
3.91
Quick Ratio
3.10

Sales & Book Value

Annual Sales
$120.80 million
Price / Sales
4.03
Cash Flow
$0.31 per share
Price / Cash Flow
110.03
Book Value
$7.79 per share
Price / Book
4.37

Miscellaneous

Outstanding Shares
14,298,000
Free Float
13,025,000
Market Cap
$486.56 million
Optionable
Optionable
Beta
1.37

Social Links

Metaverse Stocks And Why You Can't Ignore Them Cover

Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

This page (NASDAQ:SRDX) was last updated on 9/4/2025 by MarketBeat.com Staff
From Our Partners